3D hypoxia-mimicking and anti-synechia hydrogel enabling promoted neovascularization for renal injury repair and regeneration

• Published in: Materials today bio 2023-08, Vol.21, p.100694-100694, Article 100694
• Main Authors: Zhang, Yuehang, Yu, Lei, Qiu, Renjie, Cao, Lisha, Ye, Genlan, Lin, Rurong, Wang, Yongqin, Wang, Guobao, Hu, Bianxiang, Hou, Honghao
• Format: Article
• Language: English
• Subjects: Angiogenesis; Anti-synechia; Deferoxamine (DFO); Full Length; Hypoxia-mimicking; Renal tissue engineering; Sustained release
• ISSN: 2590-0064; 2590-0064
• DOI: 10.1016/j.mtbio.2023.100694

In-situ renal tissue engineering is promising yet challenging for renal injury repair and regeneration due to the highly vascularized structure of renal tissue and complex high-oxidative stress and ischemic microenvironment. Herein, a novel biocompatible 3D porous hydrogel (DFO-gel) with sustained release capacity of hypoxia mimicking micromolecule drug deferoxamine (DFO) was developed for in-situ renal injury repair. In vitro and in vivo experimental results demonstrated that the developed DFO-gels can exert the synchronous benefit of scavenging excess reactive oxygen species (ROS) regulating inflammatory microenvironment and promoting angiogenesis for effective renal injury repair by up-regulating hypoxia-inducible factor-1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF). The in-situ neogenesis of neonatal glomerular- and tubular-like structures in the implanted areas in the partially nephrectomized rats also suggested the potential for promoting renal injury repair and regeneration. This multifunctional hydrogel can not only exhibit the sustained release and promoted bio-uptake capacity for DFO, but also improve the renal injured microenvironment by alleviating oxidative and inflammatory stress, accelerating neovascularization, and promoting efficient anti-synechia. We believe this work offers a promising strategy for renal injury repair and regeneration. Herein, a novel biocompatible 3D porous hydrogel (DFO-gel) with sustained release capacity of hypoxia mimicking micromolecule drug deferoxamine (DFO) was developed for in-situ renal injury repair by promoted neovascularization and anti-synechia performance. [Display omitted]